ICON Plc Stock News

ICON Public Limited Company (NASDAQ:ICLR ) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Barry Balfe - Chief Operating Officer Kate Haven - Vice President of Investor Relations Nigel Clerkin - Chief Financial Officer Steven A. Cutler - CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division David Howard Windley - Jefferies LLC, Re...

ICON may be relatively undervalued, trading at a ~10% discount to IQVIA and offering an attractive ~7% free cash flow yield that markets seem to be responding to now. The CRO sector faces near-term headwinds from a weak biotech funding environment related to high interest rates and associated increased clinical trial cancellations and delays. Q2 is indicating to markets that there will eventual...

DUBLIN--(BUSINESS WIRE)--ICON Announces Results of Annual General Meeting.

DUBLIN--(BUSINESS WIRE)--ICON Reports Second Quarter 2025 Results.

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the average phase 1 performa...

According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (ICLR 0.92%) by selling 16,096 shares. The transaction was valued at $2.58 million.

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company's leadership position in the clinical research industry, cutting-edge innovation, its efforts in inclusion and sustainability, and as an employer of choice. Acknowledgin...

The DCF model suggests that ICON is undervalued by 98.23%. Between 2018 and 2024, the company's revenues increased by 219.04% and by 145.30%, respectively. This year, ICLR will implement a program to repurchase $750 million of its outstanding common shares.